Innovative Octet® Biolayer Interferometry (BLI) Approach For Non-Disruptive And Fast AAV Capsid Ratio Determination In Complex Biological Matrices
By Tianfang Ge and David Apiyo
Utilized to treat numerous human diseases, AAV vectors are the leading platform for gene delivery. However, during the development and production process, AAV samples often contain a mixture of full, partially full, and empty capsids. This variability necessitates accurate product characterization, particularly in determining the empty to full capsid ratios (E/F ratios). Current methods for measuring these ratios tend to be costly and time-consuming, and they face several other limitations, making it challenging to identify an ideal, cost-effective solution.
The Octet® AAVX Biosensor was designed to provide the rapid, real-time, high-throughput measurement of AAV capsid titer in samples throughout the AAV workflow. It enables quality checks, quick process optimization, and improved productivity. The AAVX Biosensors have broad specificity, covering 10 different serotypes, and provide highly precise measurements with a dynamic quantitation range from 8.5E8 to 1.0E13 vp/mL. Additionally, these biosensors are compatible with various sample matrices encountered during upstream and downstream processing, allowing for the analysis of crude samples without the need for treatment or purification. By simply diluting the sample and using the appropriate reference standards, the Octet® AAVX Biosensor can also be used to determine E/F ratios in less than 60 minutes with minimal assay optimization.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Drug Discovery Online? Subscribe today.